Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive 

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-12937

Aust, M C; Reimers, K; Repenning, C; Stahl, F; Jahn, S; Guggenheim, M; Schwaiger, N; Gohritz, A; Vogt, P M (2008). Percutaneous collagen induction: minimally invasive skin rejuvenation without risk of hyperpigmentation - fact or fiction? Plastic and Reconstructive Surgery, 122(5):1553-1563.

[img]PDF - Registered users only
10Mb

Abstract

BACKGROUND: Photoaging is generally treated by ablative procedures that injure the epidermis and basal membrane and lead to fibrosis of the papillary dermis. Damaging the epidermis significantly can cause potential adverse effects such as dyspigmentation. It was recently shown in clinical trials that percutaneous collagen induction therapy is an alternative for safely treating wrinkles and scars and for smoothening the skin without the risk of dyspigmentation. METHODS: The purpose of this study was to increase current knowledge regarding whether percutaneous collagen induction therapy presents an effective means for skin rejuvenation without risk of dyspigmentation, as the authors' clinical data suggested. Fifty-six rats were assigned to three groups: group A (n = 24), percutaneous collagen induction therapy plus skin care; group B (n = 24), skin care; and group C (n = 8) controls. The authors evaluated the effect of percutaneous collagen induction therapy on the epidermis, melanocytes, and the pigmentation markers interleukin-10 and melanocyte-stimulating hormone. RESULTS: Percutaneous collagen induction therapy left the epidermis intact without any damage to the stratum corneum, any other layers of the epidermis, or the basal membrane. No signs of dermabrasive reduction of epidermal thickness were evident 24 hours after the procedure. The number of melanocytes neither increased nor decreased in any of the groups. DNA microarray experiments demonstrated that interleukin-10 was increased in percutaneous collagen induction therapy-treated skin after 2 weeks. Concerning the MC1R (melanocyte-stimulating hormone) gene, gene expression microarray analysis indicated a faint down-regulation both 24 hours and 2 weeks after percutaneous collagen induction therapy. CONCLUSION: Percutaneous collagen induction therapy offers a modality with which to rejuvenate and improve skin appearance and quality without risk of dyspigmentation.

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Reconstructive Surgery
04 Faculty of Medicine > University Hospital Zurich > Division of Surgical Research
DDC:610 Medicine & health
Language:English
Date:November 2008
Deposited On:13 Feb 2009 14:09
Last Modified:27 Nov 2013 21:25
Publisher:Lippincott Wiliams & Wilkins
ISSN:0007-1226
Publisher DOI:10.1097/PRS.0b013e318188245e
PubMed ID:18971740
Citations:Web of Science®. Times Cited: 16
Google Scholar™

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page